Only indication is in the therapy of C. difficile infection.
Possibility of accumulation in severe renal dysfunction
Oral/rectal therapy:
Bile acid sequestrates may diminish the therapeutic effects of vancomycin.
No systemic absorption.
May increase vancomycin resistant Enterococci colonization in the gut.
LU code for outpatient use (maximum funded dose of 125 mg QID for all codes)
Antimicrobial class: Glycopeptide
Pregnancy category: C (Sanford)/B (Briggs)
Average serum half life: N/A - poor absorption
Biliary penetration: None
Lung penetration: None
CSF penetration: None
Urine penetration: None